Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same author

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026
Same author

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Cancer discovery·2026
Same author

Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914].

JTO clinical and research reports·2026
Same author

Corrigendum to "KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status" [Cancer Treatment and Research Communications 47 (2026) 101227].

Cancer treatment and research communications·2026
Same author

KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.

Cancer treatment and research communications·2026

Related Experiment Video

Updated: Apr 20, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K

Diffuse high intensity PD-L1 staining in thymic epithelial tumors.

Sukhmani K Padda1, Jonathan W Riess, Erich J Schwartz

  • 1*Division of Oncology, Department of Internal Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA; †Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA; ‡Department of Pathology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA; and §Department of Health and Research Policy, Stanford University School of Medicine, Stanford, CA.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|November 18, 2014
PubMed
Summary

Programmed death receptor ligand-1 (PD-L1) is highly expressed in thymic epithelial tumors (TETs), correlating with aggressive histology and worse survival. This finding supports clinical trials of PD-L1/PD-1 blockade therapies for TETs.

More Related Videos

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

21.8K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.8K

Related Experiment Videos

Last Updated: Apr 20, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K
Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

21.8K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.8K

Area of Science:

  • Oncology
  • Immunology
  • Pathology

Background:

  • Immune checkpoint blockade targeting the programmed death receptor ligand-1 (PD-L1)/PD-1 pathway shows clinical efficacy in various cancers.
  • PD-L1 expression is an emerging predictive biomarker for response to immune checkpoint inhibitors.
  • Thymic epithelial tumors (TETs) are rare thoracic malignancies with limited therapeutic options.

Purpose of the Study:

  • To investigate the expression patterns of PD-L1 in TETs.
  • To correlate PD-L1 expression with clinicopathological features and patient outcomes.
  • To explore the potential of PD-L1/PD-1 pathway-targeted therapies in TETs.

Main Methods:

  • A tissue microarray (TMA) comprising 69 TETs and 17 thymic controls was constructed.
  • PD-L1 expression was assessed using immunohistochemistry and scored based on staining intensity.
  • Cases were categorized as PD-L1 high or PD-L1 low based on epithelial component staining.

Main Results:

  • PD-L1 high expression was significantly more frequent in TETs (68.1%) compared to controls (17.6%).
  • Higher PD-L1 intensity correlated with more aggressive World Health Organization (WHO) histological subtypes (B2/B3/C).
  • PD-L1 high TETs were associated with significantly worse overall survival (HR: 5.40) and a trend for worse event-free survival (HR: 2.94).

Conclusions:

  • PD-L1 is frequently expressed in the epithelial component of TETs, with higher levels linked to aggressive disease.
  • PD-L1 expression in TETs is associated with poorer prognosis.
  • These findings provide a rationale for investigating anti-PD-1/PD-L1 therapies in TETs.